AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.
Following the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.
Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with AC Immune SA after disappointing study results. It has handed the global rights to Crenezumab and Semorinemab back to the Lausanne-based biotech.
After the EU Parliament’s Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft law on new genomic techniques.
AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.
Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.
Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.